# Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

> **NCT00183976** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 15 (—)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Burkitt Lymphoma
- Primary Effusion Lymphomas

## Interventions

- **DRUG:** Pegylated Liposomal Doxorubicin (Doxil) and Rituximab

## Key facts

- **NCT ID:** NCT00183976
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2005-09
- **Final completion:** 2006-01
- **Target enrollment:** 15 (—)
- **Why stopped:** Insufficient Accrual
- **Last updated:** 2014-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00183976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00183976, "Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00183976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*